Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response

Breast Cancer Research and Treatment

Volumn 89, Issue 2, 2005, Pages 135-143

  Rydén, Lisa ^a   Stendahl, Maria ^a   Jonsson, Håkan ^b   Emdin, Stefan ^b   Bengtsson, Nils O ^b   Landberg, Göran ^a  

^a LUND UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Adjuvant tamoxifen treatment; Breast cancer; Treatment prediction; VEGF A; VEGFR2

Indexed keywords

ANGIOGENIC FACTOR; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTECTOMY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL TIME; TISSUE MICROARRAY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 13844296572     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-1655-7     Document Type: Article

References (26)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114): 1451-1467, 1998.
2. Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2): 101-112, 2002.
3. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10(1 Pt 2): 346S-354S, 2004.
4. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10(1 Pt 2): 331S-336S, 2004.
5. Nahta R, Hortobagyi GN, Esteva FJ: Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8(1): 5-17, 2003.
6. Argiris A, Wang CX, Whalen SG, DiGiovanna MP: Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10(4): 1409-1420, 2004.
7. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18(7): 1423-1431, 2000.
8. Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 5(2): 101-111, 1999.
9. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60(2): 203-212, 2000.
10. Kranz A, Mattfeldt T, Waltenberger J: Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84(3): 293-298, 1999.
11. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G: Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82(3): 147-154, 2003.
12. Xie B, Tam NN, Tsao SW, Wong YC: Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Brit J Cancer 81(8): 1335-1343, 1999.
13. Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA: Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 9(4): 1253-1258, 2003.
14. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijervan Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61(14): 5407-5414, 2001.
15. Coradini D, Biganzoli E, Pellizzaro C, Veneroni S, Oriana S, Ambrogi F, Erdas R, Boracchi P, Daidone MG, Marubini E: Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen. Brit J Cancer 89: 268-270, 2003.
16. Castiglione M, Gelber RD, Goldhirsch A: Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol 8(3): 519-526, 1990.
17. Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam CM, Lindtner J, Fey MF, Senn HJ, Coates AS, Collins J, Goldhirsch A: Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 21(24): 4517-4523, 2003.
18. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM: Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60(12): 3183-3190, 2000.
19. Guo P, Fang Q, Tao HQ, Schafer CA, Fenton BM, Ding I, Hu B, Cheng SY: Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. Cancer Res 63(15): 4684-4691, 2003.
20. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2): 85-95, 1993.
21. Garvin S, Dabrosin C: Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63(24): 8742-W8748, 2003.
22. De Paola F, Granato AM, Scarpi E, Monti F, Medri L, Bianchi S, Amadori D, Volpi A: Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer 98(2): 228-233, 2002.
23. Callagy G, Dimitriadis E, Harmey J, Bouchier-Hayes D, Leader M, Kay E: Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. Appl Immunohistochem Mol Morphol 8(2): 104-109, 2000.
24. Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodino C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M: Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 81(2): 159-168, 2003.
25. Toi M, Inada K, Suzuki H, Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36(2): 193-204, 1995.
26. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama 285(7): 885-892, 2001.